Phase 1 study to assess safety, tolerability, pharmacokinetics of AMG 594 in healthy volunteers
Latest Information Update: 14 Apr 2020
At a glance
- Drugs AMG 594 (Primary)
- Indications Heart failure
- Focus Adverse reactions
- Sponsors Amgen
- 14 Apr 2020 Status changed from recruiting to suspended, to protect the safety and health of clinical study participants and healthcare professionals as well as reduce the burden on the healthcare systems fighting COVID-19.
- 09 May 2019 According to a Cytokinetics media release, the company expects the conduct of this study to continue throughout 2019.
- 20 Feb 2019 Status changed from planning to recruiting, according to a Cytokinetics media release.